IMV Inc (IMV.CA) Stock Price, Forecast & Analysis
Canada - TSX:IMV - CA44974L3011 - Common Stock
IMV.CA Key Statistics, Chart & Performance
The current stock price of IMV.CA is 1.12 CAD. In the past month the price increased by 55.56%. In the past year, price decreased by -92.91%.
IMV.CA Latest News, Press Relases and Analysis
IMV.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 470.58M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 406.00M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 179.49M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 118.44M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24.88 | 54.57M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 34.18M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 28.67M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 24.31M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 16.56M | ||
| MPH.CA | MEDICURE INC | N/A | 13.05M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 10.72M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 6.77M |
Related stock screener links
About IMV.CA
Company Profile
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 63 full-time employees. The company went IPO on 2007-10-24. The firm is focused on developing a portfolio of therapies based on DPX, an immune-educating technology platform, that is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its lead candidate, maveropepimut-S (MVP-S) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Its other candidates include DPX-RSV and DPX-COVID-19. DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is focused on developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
Company Info
IMV Inc
130 Eileen Stubbs Ave Suite 19
Dartmouth NOVA SCOTIA B3B 2C4 CA
CEO: Frederic Ors
Employees: 63
Phone: 19024921819.0
IMV Inc / IMV.CA FAQ
What does IMV Inc do?
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 63 full-time employees. The company went IPO on 2007-10-24. The firm is focused on developing a portfolio of therapies based on DPX, an immune-educating technology platform, that is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its lead candidate, maveropepimut-S (MVP-S) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Its other candidates include DPX-RSV and DPX-COVID-19. DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is focused on developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
What is the current price of IMV stock?
The current stock price of IMV.CA is 1.12 CAD. The price decreased by -1.75% in the last trading session.
Does IMV Inc pay dividends?
IMV.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of IMV stock?
IMV.CA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about IMV Inc (IMV.CA) stock?
7 analysts have analysed IMV.CA and the average price target is 28.69 CAD. This implies a price increase of 2461.38% is expected in the next year compared to the current price of 1.12.
Can you provide the market cap for IMV Inc?
IMV Inc (IMV.CA) has a market capitalization of 13.12M CAD. This makes IMV.CA a Nano Cap stock.
IMV.CA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to IMV.CA. When comparing the yearly performance of all stocks, IMV.CA is a bad performer in the overall market: 99.11% of all stocks are doing better.
IMV.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMV.CA. Both the profitability and financial health of IMV.CA have multiple concerns.
IMV.CA Financial Highlights
Over the last trailing twelve months IMV.CA reported a non-GAAP Earnings per Share(EPS) of -6.19. The EPS increased by 4.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IMV.CA Forecast & Estimates
7 analysts have analysed IMV.CA and the average price target is 28.69 CAD. This implies a price increase of 2461.38% is expected in the next year compared to the current price of 1.12.
For the next year, analysts expect an EPS growth of 20.34% and a revenue growth -80.66% for IMV.CA